News Agency
The Times

GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation

  • Written by PR Newswire

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dupert®(fulzerasib, GFH925/IBI351)for the treatment of patients with advanced non-small cell...

Read more: GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion